BioSpace News Archive

Retrophin, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine resulting in the formation of recurring cystine kidney stones.

Ascension Healthcare plc announces positive findings from its Flexiseq User Experience Study.

BioTek Instruments continues to improve laboratory workflows while simplifying the user experience with the launch of their next generation405 TS Microplate Washer.

Abveris, Inc., a global leader in contract research antibody discovery, and Harbour Antibodies H2L2 BV, a wholly-owned subsidiary of Harbour BioMed, today announced a partnership to offer fully-human antibody discovery service that combines Abveris’ antibody discovery services with the Harbour H2L2 human transgenic mouse platform.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the company has partnered with a Maryland-based site as well as the supervising physician for its upcoming expanded pivotal Cellulite Trial.

As the Clinical Evidence Evolves, the Website Provides an Updated Look at the Latest Peer-Reviewed Data

Ryan McFarlane will collaborate cross-functionally to ensure the company delivers on its commitments, and effectively applies Pharmaceutics Know-How™ across the product development & supply continuum.

Vendors Included in the Cool Vendor Report are Interesting, New and Innovative

Pfizer Inc. (NYSE:PFE) today announced top-line results from a Phase 4 study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema.

Stem cell-derived islets successfully reduce insulin requirements in diabetic non-human primates